Ricky Sharma
Follow
Get notifications in MyBN when activity occurs.
Ricky Sharma
Non-Executive Director / OncoSil Medical
Professor Ricky Sharma is an international authority on the translation of radiobiology from the laboratory to the clinic, and on the multi-modality treatment of cancer with precision radiotherapy.
Prof Sharma is the vice president of clinical affairs at Varian, a Siemens Healthineers company. He is also an honorary consultant in clinical oncology at University College London (UCL) Hospitals, where he has a clinical practice in radiotherapy and chemotherapy. Prof Sharma has led a research team at UCL that translated discoveries in radiotherapy research to clinical trials to improve treatment for patients with cancer. He was chair of radiation oncology at UCL and a scientific group leader at the UCL Cancer Institute.
Prof Sharma was previously an associate professor at the University of Oxford, chair of working groups for NHS/NICE evaluations of novel radiotherapy treatments, and an honorary consultant in clinical oncology at Oxford University Hospitals.
He has over 200 publications in peer-reviewed scientific journals, including Lancet and Nature journals.
Prof Sharma is the vice president of clinical affairs at Varian, a Siemens Healthineers company. He is also an honorary consultant in clinical oncology at University College London (UCL) Hospitals, where he has a clinical practice in radiotherapy and chemotherapy. Prof Sharma has led a research team at UCL that translated discoveries in radiotherapy research to clinical trials to improve treatment for patients with cancer. He was chair of radiation oncology at UCL and a scientific group leader at the UCL Cancer Institute.
Prof Sharma was previously an associate professor at the University of Oxford, chair of working groups for NHS/NICE evaluations of novel radiotherapy treatments, and an honorary consultant in clinical oncology at Oxford University Hospitals.
He has over 200 publications in peer-reviewed scientific journals, including Lancet and Nature journals.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1331st | Discovery Africa | -41% | 4% |
| 1514th | Eastern Resources | -53% | 11% |
| 1765th | OncoSil Medical | -72% | -44% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 970th |  | OncoSil Medical | $1.5m |
| 1201st |  | Consolidated Financial Holdings | $0 |
| 1203rd | | Discovery Africa | $0 |
| 1209th | | Eastern Resources | $0 |
| 1210th | | 3D Resources | $0 |
1328 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Non-Executive Director, OncoSil Medical | 16 Feb 2022 |
